leisure time -WSS

leisure time

author：leisure time 2025-10-01 05:39:41 - browse：5283

Christine Kao/STAT

The Food and Drug Administration’s approval on Friday of two gene therapies for sickle cell disease sets up what could be an intense competition between Bluebird Bio, maker of Lyfgenia, and the partnership of Vertex Pharmaceuticals and CRISPR Therapeutics, whose drug is Casgevy.

For the first time, physicians and patients will have a choice of potentially curative treatments for an inherited disease that affects nearly 100,000 Americans.

The Vertex/CRISPR team would seem to have the edge. As the first CRISPR-based therapy, Casgevy has the advantage of being powered by the latest and buzziest biological technology, though some physicians and patients may be more comfortable with the lentiviral vector technology behind Lyfgenia, which dates back to the 1990s — even with a “black box” warning of a risk of blood cancer added to its label.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： How generative AI is inspiring dreams of a health data revolution

leisure time

WSS

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Diversifying clinical trials isn't enough to close racial gaps: study

The pink breast cancer awareness ribbon needs a redesign

Physician subsidies by hospitals soar in wake of No Surprises Act

Meta's Zuckerberg and Chan on track to put $50 billion into science

WHO may add ‘noma' to its list of neglected tropical diseases

explore

leisure time

focus

Affirmative action in medical school literally saved lives

Cassava reveals details — and problems — with Alzheimer's study

In age of alternative facts, a scholarly course on calling out crap

'Make People Better': The CRISPR babies story you probably don't know

What does generative AI mean for health care? We asked experts

First Opinion Podcast: How to protect health care in times of war

Dobbs anniversary: the lost opportunity of abortion as health care

Humana sues Biden admin over Medicare Advantage audit rule

Medical leaders decry Supreme Court decision on affirmative action

Amazon on where the company's health care bets are headed next

hotspot

Physician subsidies by hospitals soar in wake of No Surprises Act

Emergency medicine has repudiated 'excited delirium.' Now what?

Testing for cancer recurrence creates a new limbo for patients

CDC recommends rationing of RSV shot due to shortages

Readout Newsletter: XBI biotech index, Akero Therapeutics

First Opinion Podcast: How to protect health care in times of war

knowledge

leisure time

focus

focus